NF‐κ B in liver diseases: a target for drug therapy
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
There are five nuclear factor‐κ B (NF‐κ B) transcription factors with important roles in innate immunity, liver inflammation, fibrosis and apoptosis prevention. Several inhibitors of NF‐κ B, like caffeic acid, captopril, curcumin, pyrrolidine dithiocarbamate, resveratrol, silymarin and thalidomide, have demonstrated antinecrotic, anticholestatic, antifibrotic and anticancer activities in the liver. A link between inflammation and hepatocellular carcinoma through the NF‐κ B pathway has been observed, providing ample experimental support for the tumor‐promoting function of NF‐κ B in various models of cancer. NF‐κ B has been associated with the induction of proinflammatory gene expression and has attracted interest as a target for the treatment of inflammatory disease. However, despite much attention being focused on the deleterious effects of NF‐κ B, activation of this factor during the resolution of inflammation is associated with the production of antiinflammatory molecules like interleukin (IL)‐10 and the onset of apoptosis. This suggests that NF‐κ B has an antiinflammatory role in vivo involving the regulation of the resolution of inflammation. Also, NF‐κ B promotes liver regeneration by upregulating IL‐6 and other molecules like hepatocyte growth factor. It has been postulated that the beneficial properties of NF‐κ B are due to p50 homodimers, whose activation prevents cholestatic and chronic liver injury. More basic understanding on the function of the diverse NF‐κ B factors is urgently needed in different physiological and pathological conditions, because depending on the subunit composition of the dimmer, the disease and the stage of the illness, inhibition of the factor may result in a beneficial or in a deleterious response. Copyright © 2008 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
NF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709
Multiple biological activities of curcumin: A short review
Maheshwari, R. K., Singh, A. K., Gaddipati, J., & Srimal, R. C. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.007 · Cited by 1,674
Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice
Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto, G., Furth, E. E., Poli, V., & Taub, R. (1996) · Science · doi:10.1126/science.274.5291.1379 · Cited by 1,538
Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells.
Schreck, R., Meier, B., Männel, D. N., Dröge, W., & Baeuerle, P. A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.5.1181 · Cited by 1,508
Fujiwara, N., & Kobayashi, K. (2005) · Current Drug Target -Inflammation & Allergy · doi:10.2174/1568010054022024 · Cited by 1,420
Huh, C.-G., Factor, V. M., Sánchez, A., Uchida, K., Conner, E. A., & Thorgeirsson, S. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306068101 · Cited by 750
Li, Y., Schwabe, R. F., DeVries-Seimon, T., Yao, P. M., Gerbod-Giannone, M.-C., Tall, A. R., Davis, R. J., Flavell, R., Brenner, D. A., & Tabas, I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501759200 · Cited by 421
The EGF receptor is required for efficient liver regeneration
Natarajan, A., Wagner, B., & Sibilia, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704126104 · Cited by 320
IKKβ Is Required for Prevention of Apoptosis Mediated by Cell-Bound but Not by Circulating TNFα
Maeda, S., Chang, L., Li, Z.-W., Luo, J.-L., Leffert, H., & Karin, M. (2003) · Immunity · doi:10.1016/s1074-7613(03)00301-7 · Cited by 286
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“Indeed, several studies have shown that inhibition of NF-κB activity protects from hepatic fibrosis in-vivo [157].”
BackgroundSilymarin as Supportive Treatment in Liver Diseases: A Narrative Review
Gillessen, A., & Schmidt, H. H.-J. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01251-y · Cited by 490
The Inflammation and Liver Cancer
Bishayee, A. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-0348-0837-8_16 · Cited by 255
Brenjian, S., Moini, A., Yamini, N., Kashani, L., Faridmojtahedi, M., Bahramrezaie, M., Khodarahmian, M., & Amidi, F. (2020) · American Journal of Reproductive Immunology · doi:10.1111/aji.13186 · Cited by 128
Metadata
- Authors
- Muriel, P.
- Venue
- Journal of Applied Toxicology
- Publisher
- Wiley
- Published
- 2008-10-20
- Volume
- 29
- Issue
- 2
- Pages
- 91-100
- ISSN
- 0260-437X (ISSN-L)
- 1099-1263
- OpenAlex
- W1988149166
- Cited by
- 170
- References
- 15
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.